HUP0103423A3 - Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection - Google Patents

Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection

Info

Publication number
HUP0103423A3
HUP0103423A3 HU0103423A HUP0103423A HUP0103423A3 HU P0103423 A3 HUP0103423 A3 HU P0103423A3 HU 0103423 A HU0103423 A HU 0103423A HU P0103423 A HUP0103423 A HU P0103423A HU P0103423 A3 HUP0103423 A3 HU P0103423A3
Authority
HU
Hungary
Prior art keywords
ribavirin
infection
combination therapy
interferon alpha
chronic hepatitis
Prior art date
Application number
HU0103423A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22151354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0103423(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of HUP0103423A2 publication Critical patent/HUP0103423A2/hu
Publication of HUP0103423A3 publication Critical patent/HUP0103423A3/hu
Publication of HU230432B1 publication Critical patent/HU230432B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HU0103423A 1998-05-15 1999-05-13 Ribavirint és alfa-interferont tartalmazó kombinált terápia vírusellenes kezelésben nem részesült, krónikus hepatitis C fertőzött paciensek kezelésében HU230432B1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7956698A 1998-05-15 1998-05-15
US09/079,566 1998-05-15
PCT/US1999/007037 WO1999059621A1 (en) 1998-05-15 1999-05-13 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection

Publications (3)

Publication Number Publication Date
HUP0103423A2 HUP0103423A2 (hu) 2002-01-28
HUP0103423A3 true HUP0103423A3 (en) 2003-11-28
HU230432B1 HU230432B1 (hu) 2016-06-28

Family

ID=22151354

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103423A HU230432B1 (hu) 1998-05-15 1999-05-13 Ribavirint és alfa-interferont tartalmazó kombinált terápia vírusellenes kezelésben nem részesült, krónikus hepatitis C fertőzött paciensek kezelésében

Country Status (23)

Country Link
EP (3) EP0956861B1 (hu)
JP (2) JP5281726B2 (hu)
KR (1) KR100694345B1 (hu)
CN (1) CN1230198C (hu)
AR (1) AR019551A1 (hu)
AT (1) ATE216591T1 (hu)
AU (2) AU766597B2 (hu)
BR (1) BR9910505A (hu)
CA (1) CA2331823A1 (hu)
CZ (1) CZ300540B6 (hu)
DE (1) DE69901321T2 (hu)
DK (1) DK0956861T3 (hu)
ES (1) ES2172288T3 (hu)
HK (1) HK1021131A1 (hu)
HU (1) HU230432B1 (hu)
IL (3) IL139220A0 (hu)
MY (1) MY129244A (hu)
NO (1) NO330715B1 (hu)
NZ (1) NZ507621A (hu)
PT (1) PT956861E (hu)
SK (1) SK288038B6 (hu)
TW (1) TWI277424B (hu)
WO (1) WO1999059621A1 (hu)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140143A2 (en) * 1998-12-18 2001-10-10 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
SI20976A (sl) * 1999-12-23 2003-02-28 Icn Pharmaceuticals, Inc. Sestavki in postopki za L-nukleozide, L-nukleotide in njihove analoge
JP4536194B2 (ja) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 安定な注射用製剤
AU2001259063A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20030036189A (ko) 2000-05-26 2003-05-09 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
WO2002032414A2 (en) * 2000-10-18 2002-04-25 Schering Corporation Ribavirin-pegylated interferon alfa hcv combination therapy
EP1536839B1 (en) * 2001-11-09 2010-09-15 Intarcia Therapeutics, Inc Combination therapy comprising omega-interferon for treating infection with hepatitis c virus or yellow fever virus
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
DE14169110T1 (de) 2002-06-28 2022-05-12 Centre National De La Recherche Scientifique -Cnrs- Modifizierte 2'- und 3'-Nukleosid-Prodrugs zur Behandlung von Flaviridae-Infektionen
AU2003248748A1 (en) 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
RU2005133093A (ru) * 2003-03-28 2006-07-27 Фармассет, Инк. (Us) Соединения для лечения флавивирусных инфекций
CA2520148A1 (en) * 2003-04-01 2004-12-23 Intermune, Inc. Compositions and methods for treating coronavirus infection and sars
CA2521650A1 (en) * 2003-04-17 2004-10-28 Ares Trading S.A. Interferon beta in severe acute respiratory syndrome (sars)
US7429572B2 (en) 2003-05-30 2008-09-30 Pharmasset, Inc. Modified fluorinated nucleoside analogues
CA2527711A1 (en) * 2003-06-09 2004-12-16 Genome Institute Of Singapore Inhibition of sars coronavirus infection with clinically approved antiviral drugs
JP2007501806A (ja) * 2003-08-13 2007-02-01 ハワード ジェイ． スミス アンド アソシエイツ ピーティーワイ エルティーディー ウィルス感染を治療する方法
AR045870A1 (es) * 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
WO2006031725A2 (en) 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
DK1976516T3 (da) * 2006-01-09 2013-07-15 Romark Lab Lc Behandling af viral hepatitis
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
BRPI0814363A2 (pt) 2007-07-25 2015-01-27 Biolex Therapeutics Inc Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
JP2012526149A (ja) 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
WO2012045704A1 (en) * 2010-10-05 2012-04-12 Novartis Ag New treatments of hepatitis c virus infection
AR084044A1 (es) 2010-11-30 2013-04-17 Pharmasset Inc Compuestos 2’-espiro-nucleosidos
JP6253991B2 (ja) * 2011-03-02 2017-12-27 ジェローム シェンターク， 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法
JP6073897B2 (ja) 2011-09-16 2017-02-01 ギリアド ファーマセット エルエルシー Ｈｃｖを処置するための方法
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
ES2771458T3 (es) 2013-01-31 2020-07-06 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales
PL3650014T3 (pl) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Preparat złożony dwóch związków przeciwwirusowych

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
DK0730470T3 (da) * 1993-11-10 2002-06-03 Enzon Inc Forbedrede interferonpolymerkonjugater
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
JP2000507917A (ja) * 1995-11-02 2000-06-27 シェーリング コーポレイション 持続的低用量サイトカイン注入治療
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
CA2298543A1 (en) 1997-08-13 1999-02-25 James Barry Loading and release of water-insoluble drugs
ES2162393T3 (es) * 1997-09-21 2001-12-16 Schering Corp Terapia de combinacion para erradicar el hcv-rna detectable en pacientes con infeccion de hepatitis c cronica.

Also Published As

Publication number Publication date
CN1309568A (zh) 2001-08-22
EP2305287A1 (en) 2011-04-06
NZ507621A (en) 2002-11-26
BR9910505A (pt) 2001-01-02
KR20010043624A (ko) 2001-05-25
AU2005220271B9 (en) 2010-12-09
JP5281726B2 (ja) 2013-09-04
DE69901321D1 (de) 2002-05-29
SK288038B6 (en) 2013-01-02
CA2331823A1 (en) 1999-11-25
EP1213029A1 (en) 2002-06-12
DK0956861T3 (da) 2002-07-01
HUP0103423A2 (hu) 2002-01-28
MY129244A (en) 2007-03-30
IL207259A0 (en) 2010-12-30
WO1999059621A1 (en) 1999-11-25
AU2005220271B8 (en) 2010-11-18
EP0956861A1 (en) 1999-11-17
PT956861E (pt) 2002-08-30
NO20005755L (no) 2001-01-12
AU3860099A (en) 1999-12-06
AU2005220271A1 (en) 2005-11-03
AR019551A1 (es) 2002-02-27
SK17102000A3 (sk) 2001-05-10
KR100694345B1 (ko) 2007-03-12
CN1230198C (zh) 2005-12-07
ATE216591T1 (de) 2002-05-15
HK1021131A1 (en) 2000-06-02
IL207259A (en) 2016-08-31
AU766597B2 (en) 2003-10-16
AU2005220271B2 (en) 2005-11-03
TWI277424B (en) 2007-04-01
HU230432B1 (hu) 2016-06-28
CZ20004177A3 (cs) 2001-04-11
NO330715B1 (no) 2011-06-20
IL139220A0 (en) 2001-11-25
NO20005755D0 (no) 2000-11-14
ES2172288T3 (es) 2002-09-16
JP2011173898A (ja) 2011-09-08
JP2002515453A (ja) 2002-05-28
IL139220A (en) 2013-02-28
CZ300540B6 (cs) 2009-06-10
EP0956861B1 (en) 2002-04-24
DE69901321T2 (de) 2002-12-12

Similar Documents

Publication Publication Date Title
IL207259A0 (en) Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection
HUP9802324A3 (en) Use of ribavirin and interferon alpha for the treatment of hepatitis c
ZA988466B (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
IL134428A0 (en) Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
PL344794A1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
NO20031742L (no) HCV-kombinasjonsterapi med ribavirin og pegylert interferon alfa
HU9503751D0 (en) Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
AU6588598A (en) Treatment of hepatitis b infection with thymosin alpha 1 and famciclovir
TR200101085T2 (tr) Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA'nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi
ID24910A (id) Karboksilat nukleosid hemisulfat dan penggunaan dalam perlakuan infeksi viral
PL311031A1 (en) Use of concentrates comprising vwf in complex therapy in case of treatment by using anticoagulants and fibrinolitic drugs
EP1224939A4 (en) INTERFERON-BASED COMPLEX AND ITS USE IN MEDICINE
ZA988519B (en) Use of IFN-alpha and amantadine for the treatment of chronic hepatitis C
SI1311279T1 (sl) Zdravljenje hepatitisa c s timozinom, interferonom in ribavirinom
SI1077068T1 (en) Utilization of interferon alpha 5 in the treatment of viral hepatopathies
HUP0200731A3 (en) Use of pegylated interferon alpha in chronic myeloid leukemia (cml) therapy
EP1908477A3 (en) Combination of temozolomide and pegylated interferon-alpha for treating cancer
GB9725480D0 (en) Cytokines and their use in the treatment of established chronic infections and cancers

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: MERCK SHARP & DOHME CORP., US

Free format text: FORMER OWNER(S): SCHERING CORP., US